四川百利天恒药业股份有限公司关于拟申请注册发行债务融资工具的公告

Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. plans to apply for the registration and issuance of debt financing instruments to optimize its debt structure and promote sustainable development, with a proposed issuance scale of up to RMB 10 billion [1][12]. Group 1: Issuance Plan - The company intends to issue debt financing tools in the interbank market, with a maximum scale of RMB 10 billion, including but not limited to medium-term notes, short-term financing bonds, and targeted debt financing tools [1]. - The issuance will be based on actual funding needs and may occur in a single tranche or multiple tranches, with either public or private offerings [2]. - The bond issuance period will not exceed 10 years, with specific terms and scales to be determined by the board of directors based on regulations and market conditions [3]. Group 2: Use of Proceeds - The funds raised will be used for research and development, repayment of interest-bearing debts, replenishment of working capital, and/or project equity investments and mergers and acquisitions, in compliance with legal regulations [4]. Group 3: Approval and Authorization - The proposal requires approval from the shareholders' meeting and must be registered with the China Interbank Market Dealers Association before implementation [1][13]. - The board of directors is authorized to handle all matters related to the bond issuance, including determining the type, specific plan, and conditions of the bonds [9][10]. Group 4: Impact on the Company - The issuance of debt financing tools is expected to optimize the company's debt structure and support high-quality, stable, and sustainable development, aligning with the overall interests of the company and its shareholders [12].